College Point, New York Clinical Trials

A listing of College Point, New York clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 558 clinical trials
Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax

This study will find out whether people with CLL or SLL who have received treatment with venetoclax, either alone or in combination with another drug, and who are found to be MRD-negative, can stop treatment with venetoclax and remain off-treatment for 12 months or more. The researchers will also see …

lymphoid leukemia
chronic lymphocytic leukemia
bone marrow biopsy
residual tumor
antibody therapy
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
 (6.3 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +9 other locations
THE ALIGN-AR PIVOTAL TRIAL: JenaValve Pericardial TAVR Aortic Regurgitation Study

To collect information about treatment for symptomatic severe Aortic Regurgitation (AR), which affects the aortic valve in the heart. Aortic regurgitation is a condition where aortic valve in the heart does not close tightly and allows some blood to leak back into the heart chamber. Symptoms of aortic regurgitation may …

fatigue
aortic valve replacement
regurgitation
shortness of breath
New York-Presbyterian/ Columbia University Medical Center
 (6.5 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +9 other locations
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of AB928-based combination therapy in participants with metastatic castrate resistant prostate cancer (mCRPC).

measurable disease
taxane
combined modality therapy
prostatic neoplasms, castration-resistant
antiandrogen therapy
New York University, Langone Health
 (7.5 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +21 other locations
A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy

The researchers are doing this study to find out whether the study drug hydroxychloroquine can prevent infection with the COVID-19 virus, compared with placebo, in people who are receiving radiation therapy for their cancer. The placebo used in this study is a tablet that looks the same as the study …

cns neoplasms
chills
chest tightness
covid-19
sore throat
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
 (6.3 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +6 other locations
Acne study trial

hello Acne study trial Hello!Acne study trial Hello!Acne study trial Hello!Acne study trial Hello!Acne study trial Hello!

New Site with only Phone
 (9.9 away) Contact site
  • 6 views
  • 04 Aug, 2023
  • 1 location
ctgov trial 2

    dddd

Test Site
 (7.5 away) Contact site
  • 0 views
  • 20 Aug, 2020
  • 1 location
Safety Pharmacokinetics and Preliminary Efficacy of Isatuximab in Patients Awaiting Kidney Transplantation

Primary Objectives: Phase 1: To characterize the safety and tolerability of isatuximab in kidney transplant candidates. Phase 2: To evaluate the efficacy of isatuximab in desensitization of patients awaiting kidney transplantation. Secondary Objectives: Phase 2: To characterize the safety profile of isatuximab in kidney transplant candidates. To characterize the pharmacokinetic …

chronic kidney disease
nephropathy
sar650984
isatuximab
kidney transplant
Investigational Site Number 8400002
 (7.5 away) Contact site
  • 0 views
  • 12 Nov, 2020
  • +2 other locations
First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma

Primary Objectives: Dose Escalation Part A: To determine the maximum tolerated dose (MTD) of SAR442085 administered as a single agent in patients with relapsed or refractory multiple myeloma (RRMM), and determine the recommended Phase 2 dose (RP2D) for the subsequent Expansion Part B Dose Expansion Part B: To assess the …

measurable disease
cell transplantation
thalidomide
immunotherapeutic agent
refractory multiple myeloma
Investigational Site Number 8400001
 (5.2 away) Contact site
  • 0 views
  • 04 Dec, 2020
  • +7 other locations
QA_Study Trial 01

Test Comment here

QA_Site01
 (8.3 away) Contact site
  • 0 views
  • 23 Jan, 2023
  • 1 location
Preliminary Efficacy and Safety of Apremilast in the Treatment of Acne Conglobata (APACCO) updated  

Apremilast mediates its clinical effect through the cAMP-PKA-NFkappaB pathway which results in a clinical picture changes to a decrease of all signs of inflammation.Due to the NFkappaB mediated chronical inflammation in the pathogenesis of acne conglobata, a treatment with Apremilast seems to be an effective option.In this study, treatment with …

testprivacy2US
 (9.8 away)
  • 0 views
  • 14 Mar, 2022
  • +3 other locations